TOKYO -- Japanese chemical company Teijin has invested in an American venture developing a device for treating infections after prosthetic joint implant surgery, aiming to cooperate in research and commercialization.
Garwood Medical Devices was founded in 2014 and is headquartered in New York state's city of Buffalo. Its device, BioPrax, is designed to treat bacterial infections on the implants.
